NCT05857007View on ClinicalTrials.gov

CGM Utilization With IV Insulin EndoTool and Subcutaneous Insulin in the Neuro ICU

CompletedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

July 19, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Type 1 Diabetes MellitusType 2 Diabetes MellitusHyperglycemia
Interventions
DEVICE

Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids

Ten patients with hyperglycemia or/and diabetes in the neuro ICU requires subcutaneous insulin with concomitant high dose glucocorticoids will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU

Trial Locations (1)

27157

WakeForest University Health Sciences, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER